Risk Of Developing Liver Cancer After HCV Treatment

Tuesday, January 20, 2015

Hepatitis C - Benefits firms shouldn't play drug favorites: CEO

Benefits firms shouldn't play drug favorites: CEO
|
Watch Video

Regeneron Pharmaceuticals' CEO told CNBC on Tuesday that benefits companies should not try to practice medicine.

Dr. Leonard Schleifer was reacting to the recent news that Express Scripts, the country's largest pharmacy benefits manager, dropped reimbursement for Gilead Science's hepatitis C treatment because it got deep discounts from an AbbVie alternative.

Read more....

No comments:

Post a Comment